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Abstract: The aim of this work was to design and evaluate effervescent floating gastro-retentive 
drug delivery matrix tablets with sustained-release behavior using a binary mixture of 
hydroxyethyl cellulose and sodium alginate. Pentoxifylline was used as a highly water-soluble, 
short half-life model drug with a high density. The floating capacity, swelling, and drug release 
behaviors of drug-loaded matrix tablets were evaluated in 0.1 N HCl (pH 1.2) at 37nCo0.5nC. 
Release data were analyzed by fitting the power law model of Korsmeyer–Peppas. The effect 
of different formulation variables was investigated, such as wet granulation, sodium bicarbon-
ate gas-forming agent level, and tablet hardness properties. Statistical analysis was applied 
by paired sample t-test and one-way analysis of variance depending on the type of data to 
determine significant effect of different parameters. All prepared tablets through wet granula-
tion showed acceptable physicochemical properties and their drug release profiles followed 
non-Fickian diffusion. They could float on the surface of dissolution medium and sustain drug 
release over 24 hours. Tablets prepared with 20% w/w sodium bicarbonate at 50–54 N hardness 
were promising with respect to their floating lag time, floating duration, swelling ability, and 
sustained drug release profile.
Keywords: floating tablets, sodium alginate, pentoxifylline, dissolution, swelling, 
effervescent
Introduction
Poor bioavailability has been recorded for some drugs formulated in sustained-release 
dosage forms. Their narrow absorption window, lower solubility at high pH values, 
or enzymatic degradation in the intestinal or colonic environments was the reason 
of decreased bioavailability.1–5 For this, it has been a challenge to develop the oral 
sustained-release dosage form because it is difficult to keep drugs at the targeted area 
inside the gastrointestinal tract.6 Gastro retentive drug delivery systems provide dosage 
forms with longer residence time in the stomach and sustained-release behavior, which 
can improve bioavailability as well as acting locally on the stomach.7,8 Increasing gastric 
residence time can be achieved either by floating systems that cause buoyancy above 
gastric fluid,9 high-density systems that sink to the bottom of the stomach,10 bioadhesive 
systems that adhere to mucosal surfaces,11 or by expandable systems that have limited 
emptying through the stomach pylorus due to swelling or unfolding to a larger size.12
The floating drug delivery systems were described in the literature as early as 1968.13 
These systems are designed to have a bulk density lower than the gastric fluid so they 
can remain buoyant for prolonged periods of time without affecting the gastric emptying 
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rate.3,14,15 Floating drug delivery systems can be classified as 
noneffervescent systems or effervescent systems.16
Noneffervescent floating drug delivery systems swell in 
gastric fluid and maintain a relative stability of shape and bulk 
density less than the density of the gastric fluid, which assists 
the floating process of these dosage forms.17 However, effer-
vescent floating drug delivery systems based on effervescent 
components will liberate carbon dioxide due to the acidity of 
the gastric fluid. Liberated gas bubbles will be entrapped in 
the gel layer formed by hydrocolloids that produce an upward 
motion of the dosage form and maintain its buoyancy.18
The aim of this work was to design and evaluate efferves-
cent floating tablets loaded with short half-life, 1–2 hours,19 
pentoxifylline model drug, with high density,2 and water solu-
bility at 37nC of 191 mg/mL,20 using a mixture of hydroxy-
ethyl cellulose and sodium alginate gel-forming polymers. 
The effects of different variables have been investigated 
during the study such as wet granulation, ratio of sodium 
bicarbonate gas-forming agent, and tablet hardness.
Materials and methods
Materials
Pentoxifylline, sodium alginate (15–20 cP), and sodium bicar-
bonate were obtained from Sigma-Aldrich (UK), silicified 
microcrystalline cellulose (Prosolv® 90) was obtained from 
JRS Pharma (Germany), and hydroxyethy cellulose (Natrosol 
250-HHX) was generously provided by Ashland (USA). 
Magnesium stearate was supplied by MEDEX (UK).
Methods
Granulation
Powder mixture was prepared as shown in Table 1, based 
on hydroxyethyl cellulose and sodium alginate gel–forming 
agents, Prosolv® 90 as filler to enhance compression process, 
and sodium bicarbonate was added as a gas-forming agent in 
10% or 20% w/w concentration. Pentoxifylline was used as 
a hydrophilic model drug. All powders were passed through 
180 Mm to remove any powder aggregations. However, 
sodium alginate was used in particle size cut of 350 Mm to 
overcome the compression problem that was faced by using 
180-Mm-size cut.
Mixing was done using a turbula mixer (Glen Creston 
Ltd, UK) at a rotation speed of 60 rpm for 10 minutes. The 
powder blends were poor flowable as shown in Table 2, 
and it was impossible to press them automatically by using 
tableting machine.
Wet granulation was used to enhance powder flowability 
where powder mixtures were wetted with 0.5% w/w water 
and mixed for 10 minutes using Kenwood ChefKneader 
(Thorn Domestic Appliances Ltd, UK) then passed through 
a 1,000 Mm sieve. The granules were dried by using drying 
oven (SciQuio Ltd, UK) at 60nC overnight.21 Dried granules 
with particle size cut 853 Mm were collected.
Powder mixtures and granules evaluation
Both powder mixtures and prepared granules were 
evaluated.
Moisture content
Mettler Toledo HG53 Halogen Moisture Analyzer 
(Switzerland) was used to measure moisture content in 1 g 
powder mixture before and after granulation. Measurements 
were done in triplicate and mean values o standard deviation 
(SD) were presented.
Carrs index
Bulk and tapped volumes of 50 g sample were measured by 
the tapping apparatus Copley JV1000 (UK). Bulk and tapped 
densities were calculated as the ratio of the powder weight to 
related powder volume. The Carr’s index (CI) was calculated 
using the following equation (1)22:
 CI
Tapped density Bulk density
Tapped density
 ¤¦¥
³
µ´  (1)
Measurements were done in triplicate and mean values o 
SD were presented.
Differential scanning calorimetry study
Differential scanning calorimetry (DSC) thermograms of 
F1 and F2 formulations (prepared originally from powder 
mixtures or granules) and pentoxifylline were obtained with 
the DSC Refrigerated Cooling System (Model Q1000, TA 
Instruments, UK). Samples of pure materials (2–6 mg) were 
Table 1&RPSRVLWLRQRISUHSDUHGÁRDWLQJWDEOHWV
Ingredients F1 (mg) F2 (mg)
Pentoxifylline 60 60
Hydroxyethyl cellulose 70 70
Sodium alginate 70 70
Prosolv® 90 50 50
Sodium bicarbonate 27.5 62.5
Magnesium stearate (0.5%) 1.4 1.6
Total weight 278.89a 314.06a
Note: aDifference in weight due to raising sodium bicarbonate content from 10% 
to 20% w/w.
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weighed and transferred into the equipment for analysis in 
sealed standard aluminum pans. The enthalpy readings were 
automatically calculated using Q1000, TA software for each 
peak. Thermal behavior of the samples was investigated at a 
scanning rate of 10nC/min, from 0nC to 300nC. These condi-
tions were based on a study by Suliman et al.23
Fourier-transform infrared spectroscopy
Infrared spectra of F1 and F2 formulations (prepared origi-
nally from powder mixtures or granules) and pentoxifylline 
were achieved using Perkin Elmer FT-IR system Spectrum 
BX series (UK), in the frequency range of 4,000–620 cm1 
at 4 cm1 resolution. A few milligrams of each sample were 
placed on the middle of the sample stage using a microspat-
ula. The sample was then compressed by twisting the top of 
the arm of sample stage clockwise.23 The data were obtained 
by Spectrum BX series software version 5.3.1.
Tablets preparation
Pentoxifylline matrix tablets were automatically pressed by a 
single-punch tableting machine (Type 3, Manesty Machines 
Ltd, UK) equipped with flat-faced punches (9.60 mm) to 
evaluate the effect of tablet hardness as well as gassing agent 
level on apparent density, floating capacity, swelling, erosion, 
and dissolution behavior.
In addition, to evaluate the possible effect of the wet 
granulation process on the tablets’ apparent density, float-
ing capacity, and dissolution behavior, a second group of 
manually pressed tablets were prepared. These tablets were 
pressed from powder blends before granulation where the 
required powder mixture was weighed, and fed manually 
into the die of the single-punch tableting machine to produce 
the desired tablets.
Moreover, the hardness of the prepared tablets was 
adjusted at three levels: A (50–54 N), B (54–59 N), and 
C (59–64 N) using a hardness tester (Model 2E/205, 
Schleuniger & Co., Switzerland). A third group of tablets 
with 0% w/w sodium bicarbonate was prepared automatically 
after wet granulation at hardness level (A) to evaluate the 
effect of effervescence and floating processes on swelling, 
erosion, and drug release behavior.
Evaluation of tablets
Tablets pressed automatically by the tableting machine were 
evaluated for tablet hardness, friability, weight uniformity, 
drug content uniformity, apparent density, floating capacity, 
swelling, erosion, dissolution, as well as release data mod-
eling. However, manually pressed tablets were evaluated 
only for apparent density, floating capacity, dissolution, and 
release data modeling.
Quality control tests
The following tablet quality control tests were conducted in 
accordance to pharmacopoeia specifications.24
Tablet hardness
Ten tablets were randomly selected, their hardness was 
examined using the tablet hardness tester, and mean values o 
SD were presented.
Tablet friability
Twenty tablets were randomly selected; initial weight was 
recorded (w
1
) and tablets were placed in the drum of the fri-
ability test apparatus (Copley FRV 1000, UK).
The drum rotation was adjusted to be 25 rpm. The 
tablets were removed, de-dusted, and accurately weighed 
(w
2
). The percentage of weight loss (F) was calculated by 
equation (2)24:
 F 
w w
w
 1 2
1
 r100%  (2)
Tablet weight uniformity
Twenty tablets were randomly selected and accurately 
weighed individually, and mean weight of all tablets and 
Table 2 Moisture content and Carrs index with statistical analysis (P-value) results of F1 and F2 formulations before and after 
granulation
Formulation Test Origin of prepared tablets P-value
Powder mixture Granules
Fl Moisture content (%) 5.37o0.06 4.13o0.17 0.005
Carrs Index 27.74o0.46 16.87o0.33 0.001
F2 Moisture content (%) 4.76o0.08 3.49o0.14 0.003
Carrs Index 28.53o2.81 17.65o0.64 0.016
Note: The data represent mean o SD of three determinations.
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percentage deviation from the mean for each tablet were 
presented.
Drug content uniformity
Ten tablets were randomly selected; each individual tablet 
was weighed then crushed using mortar and pestle. A suitable 
quantity of powder was extracted with 100 mL, 0.1 N HCl 
using shaking water bath (Model SS40-D, Grant Instruments 
Ltd, Cambridge, UK) at 37nCo0.5nC. The solution was fil-
tered through a cellulose acetate membrane (0.45 Mm). The 
drug content was determined by UV/Vis spectrophotometer 
(Model M501, Camspec Ltd, Cambridge, UK) at 274 nm 
using the calibration curve presented in Figure 1 after suit-
able dilution with 0.1 N HCl and percentages of individual 
drug content were calculated against the average drug content 
according to the specifications.
Tablet apparent density
Tablet height (h) and diameter (m) were measured by caliper 
scale (Moore and Wright Sheffield England Metric, UK). 
Tablet weight (w) and (.) the circular constant were also 
used to calculate the tablet apparent density (D) by the fol-
lowing equation (3)25:
 D
cm
w
m
g
h
3 2
2
¤
¦¥
³
µ´ ¤
¦¥
³
µ´ r r

.
 (3)
Mean values o SD were presented.
Tablet porosity
Tablet porosity a, was calculated using the following 
equation (4)26:
 a l l    	1
tablet true
 (4)
where l
tablet
 is the tablet apparent density and l
true
 is the 
true density of the powder mixture or granule samples 
measured by multipycnometer (MVP-D160-E, Quantach-
rome Instruments, USA). Five replicate measurements of 
almost 1.8 g sample were used, helium pressure was set to be 
17 psi, and the difference in helium pressure before and after 
sample loading was recorded to determine the true volume 
of the samples. Mean values o SD were presented.
7DEOHWÁRDWLQJFDSDFLW\
The time taken by the tested tablets to appear on dissolu-
tion medium surface (floating lag time) and the period of 
time that the tablets constantly floated on the dissolution 
medium surface (floating duration) were determined visu-
ally throughout the drug release studies,27 and mean values 
o SD were presented.
Swelling and erosion studies
Primarily, the initial weights of three tablets were recorded. 
Dissolution medium uptake (DMU) and mass loss (ML) per-
centage of the tablets were determined using USP dissolution 
apparatus II (Erweka GmbH, Germany) under the same condi-
tions of drug release study. Tablets were carefully withdrawn 
from the medium at 0.5, 1, 2, 4, 6, 8, 12, and 24 hours. Excess 
liquid on tablet surfaces was removed by a filter paper and the 
tablets were weighed and then dried in drying oven at 60nC 
until a constant dry weight was achieved. Swelling rate and 
mass loss rate were calculated by equations (5) and (6)28:
 % DMU
W W
W
w t
t
 ¤
¦
¥¥
³
µ
´´ r100  (5)
 % ML
W W
W
t d
t
 ¤
¦
¥¥
³
µ
´´ r100  (6)
where W
i
 is the initial weight of the tablet, W
w
 is the wet 
weight of the tablet, and W
d
 is the dry weight of the tablet 
and mean values o SD were presented.
In vitro drug release studies
Drug release studies of the prepared floating tablets were 
carried out in USP dissolution apparatus II (Erweka GmbH, 
Germany) at 37nCo0.5nC, and paddle rotation was 50 rpm.24 
Tablets were placed in 900 mL of 0.1 N HCl solution 
(pH 1.2), and as mentioned earlier, pentoxifylline water 
solubility at 37nC is 191 mg/mL; therefore, dissolution of 
60 mg in 900 mL at 37nC is considered under sink condi-
tions. Suitable sample volumes were withdrawn from the 
dissolution vessels by cannula fitted with filters at 0.5, 1, 2, 
20:2
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Figure 1 Calibration curve of pentoxifylline in 0.1 N HCl.
Notes: The data represent mean o SD of three determinations. Error bars cannot 
be seen on the graph as SD values are very small.
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4, 6, 8, 12, and 24 hours. Withdrawn volumes were replaced 
with fresh medium, and drug content was determined by 
UV spectroscopy at 274 nm, and the cumulative drug release 
percentage was calculated. Each determination at each time 
point was performed in triplicate and mean values o SD 
were presented.
Release data modeling and analysis
In order to characterize pentoxifylline release mechanism, 
the power law model of Korsmeyer–Peppas (equation 7) was 
fitted to the first 60% release data.29
 
Q
Q
K tt n
c
 r
p
 (7)
where Q
t
/Q& represents the fractional drug released at 
time t, K
p
 is the release rate constant, and n is the release 
exponent.
Statistical analysis
The statistical software of SPSS 21 (SPSS Inc., Chicago, 
USA) was used to perform statistical analysis by apply-
ing paired-sample t-test, and one-way analysis of variance 
depending on the type of data. Post hoc multiple compari-
sons were applied when necessary. A P-value of 0.05 was 
considered significant.
Results and discussion
Moisture content and CI values
Table 2 shows the results of moisture content and CI values 
of F1 and F2 formulations before and after granulation. It is 
clear that the percentage of moisture content decreased sig-
nificantly (P0.05) after granulation from 5.37% and 4.76% 
to 4.13% and 3.49% in F1 and F2 formulations, respectively. 
In addition, flow characteristics of both formulations have 
been enhanced significantly (P0.05) according to CI values 
from poor to fair level.30
It is known that packing studies of powder and granules 
can be used to predict their rheological properties. These 
studies can be carried out with a tapping apparatus where 
powder or granules specific volume before and after tapping 
is measured and divided by the used masses to calculate 
bulk and tapped apparent densities to give information about 
sample rheological properties.31 It has been argued that a 
small change in apparent density before and after tapping 
indicates good flow properties.32
Moreover granulation process is one of the agglom-
eration techniques where fine solid particles are converted 
into larger ones by mixing them in the presence of binding 
liquid using suitable equipment.33 It has been reported that 
the formed granules can improve powder flowability and 
mechanical strength and can also narrow bulk density and 
porosity values.34,35
Differential scanning calorimetry
The compatibility of pentoxifylline model drug with excipients 
in F1 and F2 formulations before and after granulation was 
studied using DSC. Figure 2 represent DSC thermograms 
of pure pentoxifylline, F1 powder mixture, and F1 granules. 
Although pure pentoxifylline shows a sharp endothermic peak 
at 104.80nC, a shift to lower temperature and a decrease in peak 
intensity are noted in F1 granules and F1 powder with endother-
mic peaks at 94.64nC and 91.84nC, respectively. In addition, as 
shown in Figure 3, there is also a shift to a lower temperature 
and a decrease in peak intensity in F2 granules and F2 powder 
4
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Figure 2 Differential scanning calorimetry thermograms (Exo up) of pure pentoxifylline, F1 powder mixture, and F1 granules.
Abbreviation: Exo up, exothermic transitions up.
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with endothermic peaks at 94.10nC and 90.27nC, respectively. 
This might indicate a certain loss of drug crystallinity,36 which 
means part of the pentoxifylline crystals has been converted 
into the amorphous form during the preparation of both powder 
mixture as well as granules. Although these observations reflect 
the existence of interactions between the model drug and other 
components, as no other thermal event occurred, these interac-
tions do not necessarily indicate incompatibility.37
Fourier-transform infrared spectroscopy
Fourier-transform infrared spectroscopy was used to study the 
compatibility of the pentoxifylline model drug with excipi-
ents in F1 and F2 formulations before and after granulation. 
Figure 4 represents the IR spectra of pure pentoxifylline, F1 
powder mixture, and F1 granules, while F2 powder mixture 
and F2 granules are shown in Figure 5. The spectrum of pen-
toxifylline exhibited characteristic bands at 2,945, 1,701, and 
1,658 cm1 for –CH, –CO, and amide –CO stretching mode. 
In addition bands  were present at 1,433 cm1 for –CH
3
 defor-
mation and at 752 cm1 for –(CH
2
)n– skeletal vibration.38 The 
peaks of the model drug are also present almost at the same 
wave numbers in the spectra of drug-loaded powder mixture 
and granules of both F1 and F2 formulations, which indicates 
the absence of incompatibility between the model drug and 
the formulation excipients.
Evaluation of tablets
Tablet hardness
After granulation, tablets of F1 and F2 formulations were 
prepared successfully at level A (50–54 N), and level B 
(54–59 N) of targeted hardness as presented in Table 3. Both 
the formulations could not be prepared at the hardness level 
of 59–64 N; however, this level of hardness was achieved 
with tablets prepared from the powder mixture.
2
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Figure 3 Differential scanning calorimetry thermograms (Exo up) of pure pentoxifylline, F2 powder mixture, and F2 granules.
Abbreviation: Exo up, exothermic transitions up.
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Figure 4 Fourier-transform infrared spectra of pure pentoxifylline, F1 powder mixture, and F1 granules.
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It has been reported that the chemical composition of 
alginates affects their compression behavior, where alginates 
with low guluronic acid content behave more elastically than 
alginates with low mannuronic acid content. In addition, the 
plasticity of potassium alginates is higher than that of sodium 
alginates. However, alginates deform elastically.39 Generally, 
the granulation process might enhance elastic recovery of 
alginate molecules after compression, which could explain 
the inability to prepare tablets of both F1 and F2 formulations 
at level (C) of hardness after granulation. For this reason, the 
floating capacity, swelling, and drug release behaviors of 
drug-loaded matrix tablets were evaluated at two hardness 
levels (A and B) instead of three.
Tablet friability, weight, and drug content uniformity
Results of friability (%), average weight (g), and average 
drug content (mg) of prepared matrix tablets of both F1 
and F2 formulations are presented in Table 3. For friability 
test, there were no signs of cracked, split, or broken tablets 
at the end of the test. Additionally, all results are between 
0.60% and 0.88%, which fit British Pharmacopoeia (BP) 
limits, where tablets had friability values less than 1%.24 
In addition, as tablet hardness level increases, mass loss 
percentage decreases.
All prepared tablets of F1 and F2 formulations (Table 3) 
complied with BP specification24 with respect to weight 
uniformity test.
For content uniformity test, Table 3, results are in the 
acceptable range, indicating that all matrix tablets fit to (BP) 
criteria in which each tablet drug content was between 85% 
and 115% of related average content.24
Tablet apparent density
Apparent densities of the prepared tablets of F1 and F2 
formulations are calculated by equation (3) and the results 
are shown in Table 4. Generally, increasing tablet hardness 
level increases significantly (P0.001) the apparent density 
of all prepared tablets as shown in Table 4. This might be 
justified by the reduction in measured tablet thicknesses as 
particles become more adjacent to each other by increasing 
the compression force as shown in Table 4.
Furthermore, Table 5 shows the statistical effect of 
the granulation process on apparent density of F1 and F2 
formulations at both hardness levels. It is obvious that the 
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Figure 5 Fourier-transform infrared spectra of pure pentoxifylline, F2 powder mixture, and F2 granules.
Table 33URSHUWLHVRISHQWR[LI\OOLQHÁRDWLQJWDEOHWVRI)DQG)JUDQXOHIRUPXODWLRQV
Formulation Hardness level Hardness (kg)a Friability (%) Tablet weight (g)b Drug content (mg)a
F1 (A) 5.2o0.27 0.80 0.290o0.00 57.82o1.63
(B) 5.7o0.33 0.60 0.292o0.00 57.13o0.64
(C) NA NA NA NA
F2 (A) 5.0o0.24 0.88 0.318o0.01 56.63o0.97
(B) 5.9o0.31 0.66 0.306o0.00 53.43o1.45
(C) NA NA NA NA
Notes: aThe data represent mean o SD of 10 determinations. bThe data represent mean o SD of 20 determinations. The hardness of the prepared tablets was adjusted at 
three levels: A (5054 N), B (5459 N), and C (5964 N) using a hardness tester (Model 2E/205, Schleuniger & Co., Switzerland).
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granulation process causes a significant (P0.05) decrease in 
tablet apparent densities of F1 formulation at both hardness 
levels. In addition, a significant (P0.001) decrease is noted 
in tablet apparent density results of F2 formulation prepared 
at hardness level (A); however, a nonsignificant (P0.363) 
decrease is noted at level (B) of hardness.
It was noted that the elastic recovery of sodium alginate 
(after granulation process) effect is reduced when sodium 
bicarbonate level is increased up to 20% w/w (in F2 for-
mulation) at hardness level (B). This might be explained by 
the high true density value of sodium bicarbonate,40 which 
is 2.173 g/cm3. This high true density value in addition to 
the high compression pressure of level (B) might inverse 
the elastic recovery effect of the granulation process on the 
apparent density results of F2 formulation at hardness level 
(B) (Table 4).
Tablet porosity
Tablet porosity percentage of F1 and F2 formulations are 
presented in Figure 6. Generally, increasing tablet hardness 
level significantly (P0.05) decreases the porosity percent-
ages. This complies with the tablet thickness results presented 
in Table 4, where increasing the tablet hardness from level 
(A) to level (B) reduces the measured tablet thicknesses as 
particles become more adjacent to each other.
Furthermore, the granulation process decreases the tablet 
porosity significantly (P0.05) for F1 formulation where 
P0.001 at both hardness levels, and nonsignificantly 
(P0.05) for F2 formulation at hardness level (A) and (B). 
The effect of different treatment conditions on the production 
of cross-linked drug alginate granules has been reported by 
a previous study.41 This study demonstrated that increasing 
the water binder volume decreases porosity during the wet 
massing stage, and this reduction in porosity can delay dis-
solution media entrapment through the matrix at an early 
stage of the dissolution test. This might justify the significant 
(P0.05) reduction of porosity results of F1 formulation at 
both hardness levels. However, the nonsignificant effect of 
granulation process in F2 formulation can be justified by their 
higher content of sodium bicarbonate; as shown in Figure 6, 
increasing the level of sodium bicarbonate from 10% (in F1 
formulation) to 20% w/w (in F2 formulation) significantly 
(P0.05) decreases all tablet porosity results. For this, the 
tablet porosity results might reach a level after which no 
Table 4 Apparent density of F1 and F2 formulations before and after granulation
Formulation Hardness  
level
Origin of prepared tablets
Powder mixture Granules
Tablet apparent  
density (g/cm3)
Tablet thickness 
(cm)
Tablet apparent  
density (g/cm3)
Tablet thickness 
(cm)
F1 (A) 1.30o0.00 0.294o0.01 1.26o0.00 0.303o0.01
(B) 1.32o0.01 0.298o0.01 1.29o0.01 0.298o0.02
F2 (A) 1.34o0.00 0.322o0.01 1.32o0.00 0.327o0.00
(B) 1.36o0.01 0.316o0.01 1.36o0.01 0.318o0.02
Notes: The data represent mean o SD of three determinations. The hardness of the prepared tablets was adjusted at three levels: A (5054 N), B (5459 N), and C 
(5964 N) using a hardness tester (Model 2E/205, Schleuniger & Co., Switzerland).
Table 5 Statistical analysis (P-value) results of effect of granulation 
process on apparent density results of F1 and F2 formulations at 
different hardness levels
Formulation Hardness level P-value
F1 (A) 0.001
(B) 0.001
F2 (A) 0.001
(B) 0.363
Note:  The hardness of the prepared tablets was adjusted at three levels: A (5054 
N), B (5459 N), and C (5964 N) using a hardness tester (Model 2E/205, Schleuni-
ger & Co., Switzerland).
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Figure 6 Porosity percentage of F1 and F2 formulations before and after granulation.
Note: The hardness of the prepared tablets was adjusted at three levels: A (5054 
N), B (5459 N), and C (5964 N) using a hardness tester (Model 2E/205, Schleuni-
ger & Co., Switzerland).
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significant effect of the granulation process can be noted in 
F2 formulation.
7DEOHWÁRDWLQJFDSDFLW\
Sodium bicarbonate enhances the floating behavior of 
tablets due to the release of carbon dioxide gas, which will 
be entrapped in the formed gel layer around the tablets and 
results in reducing tablet density to facilitate the floating 
process. Table 6 represents all prepared tablet floating 
capacity results.
Statistical analysis (P-value) of changing hardness level 
on tablet floating lag time of F1 and F2 formulations origi-
nally prepared from powder mixture or granules revealed that 
changing the hardness level in both formulations prepared 
from the powder mixture causes a significant (P0.05) 
increase in the floating lag time (Table 6) where P0.003 
and P0.001 for F1 and F2, respectively. These results are 
in agreement with porosity data where increasing hardness 
level leads to decreasing tablet porosity. For this penetra-
tion of acidic medium into the matrix to react with sodium 
bicarbonate will take time, which will delay the tablet float-
ing process.
Furthermore, there is also an increase in the lag time 
measurements in formulations originally prepared from 
the granules due to changing the hardness level (Table 6). 
However, the delay in the floating lag time is not signifi-
cant (P0.05) where P0.057 and P0.461 for F1 and F2 
formulations, respectively. This can be justified by the high 
elastic recovery of sodium alginate due to the granulation 
process. This means that the formed granules can show 
higher resistance to changing the hardness from level (A) to 
level (B), which results in a nonsignificant (P0.05) effect 
on the floating lag time.
Moreover, the granulation process causes a significant 
(P0.05) increase in the tablet floating lag time compared 
to that of tablets prepared from powder mixtures before 
granulation (Table 6). This can be related to the decrease 
in the porosity level after the granulation process, which 
agrees with the study by Mukhopadhyay et al.41 For this, 
the penetration of acidic medium into the tablet matrix will 
be delayed and sodium bicarbonate will take a longer time 
to start generation of sufficient carbon dioxide bubbles to 
initiate floating process.
Furthermore, changing sodium bicarbonate concentra-
tion from 10% to 20% w/w leads to a significant (P0.05) 
decrease in lag time records of tablets prepared originally 
from powder mixture at both hardness levels, where 
P0.008 and P0.017 for level (A) and level (B), respec-
tively. Increasing sodium bicarbonate content available 
for acidic medium will enhance the rate as well as the 
efficiency of the effervescence reaction, which is repre-
sented by the shorter floating lag time results. However, 
the reduction in lag time values is not significant (P0.05) 
in tablets prepared originally from granules at levels (A) 
and (B) of hardness. This complies with what has been 
mentioned earlier about the effect of the granulation pro-
cess on the porosity level. The granulation procedure can 
reduce porosity during the wet massing stage, which will 
make it more difficult for the acidic medium to penetrate 
into the matrix structure to start effervescence reaction. 
From this, it could be indicated that the granulation process 
effect on the floating lag time results is more predominant 
than that of changing the tablet hardness or the gassing 
agent levels.
For floating duration, although, F1 tablets prepared 
originally from the powder mixture at both hardness levels 
floated for 12 hours, but there is 4 hours reduction in their 
floating duration after the granulation process. In addition, 
there is no difference in floating duration of F2 formula-
tions before and after granulation at both hardness levels, 
where they floated for 24 hours. It is clear that 20% w/w 
concentration is more effective than 10% w/w concentration 
to keep tablets on the surface of the dissolution medium for 
a longer duration of time.
Table 6)ORDWLQJODJWLPHDQGÁRDWLQJGXUDWLRQRI)DQG)IRUPXODWLRQVDWGLIIHUHQWKDUGQHVVOHYHOV
Formulation Hardness  
level
Floating lag time (min) 7RWDOÁRDWLQJGXUDWLRQK
Origin of prepared tablet Origin of prepared tablets
Powder mixturea Granulesa Powder mixture Granules
F1 (A) 0.84o0.08 6.54o1.19 12 8
(B) 1.81o0.25 9.78o1.77 12 8
F2 (A) 0.44o0.03 4.13o0.35 24 24
(B) 0.92o0.05 4.48o0.67 24 24
Notes: aThe data represent mean o SD of three determinations. The hardness of the prepared tablets was adjusted at three levels: A (5054 N), B (5459 N), and C (5964 
N) using a hardness tester (Model 2E/205, Schleuniger & Co., Switzerland).
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Swelling and erosion studies
Swelling and erosion studies of sodium alginate, hydroxy-
ethyl cellulose binary mixture based matrix tablets were used 
to make a correlation with drug release profiles and release 
mechanism. Nonfloating tablets with 0% w/w sodium bicar-
bonate concentration were used in this study beside 10% and 
20% w/w concentration to clarify the effect of the efferves-
cence process as well as the gassing agent concentration on 
swelling, erosion, and drug release results.
In addition, only tablets prepared from granules were 
subjected to swelling and erosion study because of their good 
flow properties that facilitate their automatic pressing (this 
is supported by Javaheri et al study,42 for liquisolid tablet 
formulations) by the single-punch tableting machine.
Figure 7 shows the percentage of DMU, for all prepared 
tablets, in 0.1 N HCl medium, where all records show 
continuous increase in swelling rate until 12 hours of the 
experiment.
Increasing tablet hardness from level (A) to (B) in both 
F1 and F2 formulations does not cause a significant (P0.05) 
effect in the swelling rate results. Tablets (from F2 formula-
tions) prepared at both hardness levels show a significant 
(P0.05) increase in DMU (compared to tablets prepared 
from F1 formulations).
When a tablet floats on the dissolution medium, its upper 
surface will not come in contact with the medium, while other 
surfaces will be placed under the dissolution medium surface. 
However, if it sinks after a period of time, all surfaces of 
this tablet will become completely available for the DMU. 
For this, the surface area available for water uptake and the 
floating duration can explain the lower swelling rate of F2 for-
mulation in comparison with F1 formulation (Figure 7). As 
mentioned previously, F2 formulation floats for 24 hours 
while F1 formulations float for only 8 hours and then sink 
for the rest of the experiment time. This means that the upper 
tablet surface of F1 formulation becomes available for the 
DMU after sinking and the tablet shows higher swelling rate 
by the end of the experiment.
In addition, nonfloating tablets that stay under the sur-
face of the dissolution medium for all the experiment time 
show an almost similar swelling rate profile of those of F1 
formulations as presented in Figure 7 and the difference is not 
significant (P0.05). However, F2 formulation tablets show 
significant (P0.001) lower swelling rate results than those of 
nonfloating tablets. Figure 8 represents the percentage of mass 
loss of all prepared tablets where all tablets show gradual loss 
in their masses up to almost half of their original weight at 
the end of 24 hours. Moreover, increasing hardness levels do 
not show a significant (P0.05) effect on mass loss values. 
However, changing sodium bicarbonate concentration from 
10% w/w (F1 formulations) to 20% w/w (F2 formulations) 
increases significantly (P0.05) the mass loss in F2 formu-
lations for the hardness level (A) and level (B). This can 
be explained by a higher effervescence effect due to higher 
gassing agent level, which will liberate more carbon dioxide 
bubbles. This means more mass loss from the tablet matrix 
due to the effervescence process. Furthermore, nonfloating 
tablets generally show the lowest mass loss percentage pro-
file as shown in Figure 8 and their results are significantly 
(P0.05) lower than F1 and F2 formulations.
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Notes: The data represent mean o SD of three determinations. The hardness of the prepared tablets was adjusted at three levels: A (5054 N), B (5459 N), and C (5964 
N) using a hardness tester (Model 2E/205, Schleuniger & Co., Switzerland).
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In vitro drug release studies
Dissolution profiles of both F1 and F2 formulations at differ-
ent hardness levels before and after granulation are shown in 
Figures 9 and 10. Generally, increasing the tablet hardness 
level causes a decrease in the drug release profiles of the 
tablets prepared originally from the powder mixture as well 
as from the granules. Statistically, the tablets prepared from 
the powder mixture show a significant (P0.05) decrease in 
their drug release profiles when their hardness level increases 
from level (A) to level (B).
Although Liew et al43 argued that both gel layer genera-
tion around a matrix tablet as well as its porosity will control 
the drug release process, but not the dry matrix porosity; 
however, Sanchita et al44 reported a significant difference in 
drug release from highly compressed tablets, indicating that 
there is a limit of hardness above which the porosity of a dry 
matrix will affect the penetration of the dissolution medium 
inside the tablet. Additionally, this complies with results of 
the present study for the porosity, where increasing the com-
pression force makes powder mixture particles more close to 
each other and reduces the porosity percentage significantly 
(P0.05). For this, the penetration of the dissolution medium 
into the matrix to dissolve pentoxifylline model drug is more 
difficult, which delays the drug release process.
Moreover, increasing the hardness level does not cause 
a significant (P0.05) decrease in the drug release profiles 
of the tablets prepared from the granules where P0.399 and 
P0.250 for F1 and F2 formulations, respectively. These find-
ings fit the results described earlier of the effect of changing 
the hardness level on the lag time of the tablets prepared 
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Figure 9 3HUFHQWDJHRIGUXJUHOHDVHRI)DQG)IRUPXODWLRQVÁRDWLQJWDEOHWVSUHVVHGDWOHYHO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Notes: The data represent mean o SD of three determinations. The hardness of the prepared tablets was adjusted at three levels: A (5054 N), B (5459 N), and C 
(5964 N) using a hardness tester (Model 2E/205, Schleuniger & Co., Switzerland).
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originally from the granules. This means that sodium alginate 
high elastic recovery resists the effect of increasing the hard-
ness level on the drug release profiles. Additionally, Ebube 
and Jones45 reported a minimal effect of compression force on 
acetaminophen release behavior from either hydroxypropyl 
methylcellulose or hydroxypropyl cellulose matrix tablets 
prepared with granulation.
The effect of the granulation process on drug release 
behavior from F1 and F2 formulations at different hard-
ness levels reveals that granulation process reduces drug 
release profile of all prepared tablets. A significant (P0.05) 
decrease is noted in the release profiles at level (A) of 
hardness in both F1 and F2 formulations, where P0.009 
and P0.001, respectively, and at level (B) of hardness in 
F2 formulation, where P0.001. However, the effect of the 
granulation process on the drug release process at level (B) 
of hardness in F1 formulation is not significant (P0.05). 
Totally, this complies with the Mukhopadhyay et al study41 
where increasing the water binder volume will decrease the 
porosity during the wet massing stage, and this reduction can 
delay the dissolution media entrapment through the matrix at 
an early stage of the dissolution test, which totally decreases 
the drug release process.
There is a significant (P0.05) effect of raising sodium 
bicarbonate level on the rate of drug release of all pre-
pared formulations as shown in Figure 9, where increasing 
the gassing agent concentration from 10% to 20% w/w 
increases the drug release rates of formulations prepared 
originally from powder mixture at level (A) and level (B) 
of hardness. Increasing the gassing agent level from 10% 
to 20% w/w increases pore formation in wet matrix tablets 
due to the effervescence process and the liberation of more 
carbon dioxide bubbles, which leads to higher drug release 
profiles.
On the contrary, as shown in Figure 10, increasing sodium 
bicarbonate concentration decreases significantly (P0.05) 
the rate of the drug release from formulations prepared 
originally from granules at level (A) and level (B) of hard-
ness. This complies with the swelling study results, where 
the swelling rate of F1 formulation is higher than that of F2 
(refer to Figure 7). Accordingly, a higher swelling rate indi-
cates more dissolution medium entrapment in matrix tablets 
body, which can dissolve and release more drug molecules. 
Moreover, as shown in Figure 11, nonfloating tablets show 
a drug release profile (P0.05) almost similar to that of the 
F1 formulation. However, F2 formulation tablets show a 
significant (P0.001) lower dissolution rate than those of 
nonfloating tablets.
Release data modeling and analysis
In order to evaluate the effect of different variables such 
as tablet hardness, granulation process, and gassing agent 
concentration on the drug release mechanism from prepared 
tablet formulations, the drug release data were fitted to 
Korsmeyer–Peppas equation (equation 7), which describes 
drug release from polymeric systems. It has been reported that 
a drug release mechanism can be predicted from values of 
exponent (n), where for cylindrical tablet, a value of n0.45 
indicates Case I transport or Fickian release (release by dif-
fusion), 0.45n0.89 indicates anomalous or non-Fickian 
release (release by diffusion and polymer relaxation), n0.89 
indicates Case II transport (release by polymer erosion and 
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Notes: The data represent mean o SD of three determinations. The hardness of the prepared tablets was adjusted at three levels: A (5054 N), B (5459 N), and C 
(5964 N) using a hardness tester (Model 2E/205, Schleuniger & Co., Switzerland).
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Table 7 KorsmeyerPeppas kinetic parameters of different pentoxifylline tablet formulations
Formulation Origin of prepared  
tablets
Hardness  
level
KorsmeyerPeppas
R2 n K
p
1RQÁRDWLQJ Granules (A) 0.9974 0.5871 0.2212
F1 Powder (A) 0.9710 0.2532 0.3759
(B) 0.9969 0.5057 0.2512
Granules (A) 0.9989 0.5799 0.1907
(B) 0.9990 0.6690 0.1990
F2 Powder (A) NA NA NA
(B) 0.9459 0.1503 0.4747
Granules (A) 0.9921 0.6822 0.1359
(B) 0.9907 0.6113 0.1566
Notes:1$7KHUHDUHLQVXIÀFLHQWGDWDSRLQWVRQWKHUHOHDVHSURÀOHV60% drug release to provide accurate values. The hardness of the prepared tablets was adjusted at 
three levels: A (5054 N), B (5459 N), and C (5964 N) using a hardness tester (Model 2E/205, Schleuniger & Co., Switzerland).
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Figure 11 3HUFHQWDJHRIGUXJUHOHDVHRIÁRDWLQJDQGQRQÁRDWLQJWDEOHWVSUHVVHGDWOHYHO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Notes: The data represent mean o SD of three determinations. The hardness of the prepared tablets was adjusted at three levels: A (5054 N), B (5459 N), and C 
(5964 N) using a hardness tester (Model 2E/205, Schleuniger & Co., Switzerland).
zero-order kinetics), and n0.89 indicates Super Case II 
transport (release by polymer erosion).37
As shown in Table 7, drug release results fit Korsmeyer–
Peppas equation as correlation coefficients (R2) greater than 
0.98 are obtained in most cases except for those tablets pre-
pared originally from powder mixture of F1 formulation at 
hardness level (A), and of F2 formulation at hardness level 
(B), where (R2) values are 0.9710 and 0.9459, respectively. 
Additionally, there are insufficient data points on the release 
profile 60% drug release to provide accurate values for tab-
lets prepared originally from powder mixture of F2 formula-
tion at level (A) of hardness. As shown in Table 7, increasing 
tablet hardness in F1 formulations prepared originally from 
powder mixture from level (A) to level (B) of hardness, 
change the release exponent (n) values from 0.2532 to 0.5057, 
which indicates a change in the mechanism of the drug release 
from Fickian to non-Fickian, which means involvement of 
polymer swelling or relaxation in the release process beside 
drug diffusion. However, the results of F2 formulation are not 
clear due to insufficient data points at level (A) of hardness. 
Furthermore, it has generally been noted that increasing the 
hardness from level (A) to (B) in tablets originally prepared 
from the powder mixture decreases the release rate constant 
(K
p
). This complies with in vitro drug release studies, where 
increasing the compression force makes powder mixture 
particles more close to each and reduces porosity percent-
age values. This also delays penetration of the dissolution 
medium into the matrix to dissolve the model drug, which 
decreases the drug release rates.
However, changing the hardness level in tablets prepared 
originally from granules slightly changes the exponent (n) 
values in both F1 and F2 formulations, where values are in 
the range of 0.5799–0.6822, which indicates anomalous or 
non-Fickian release mechanism. In addition, the release rate 
constant (K
p
) slightly changes by increasing the hardness 
level. This complies with in vitro drug release studies, where 
increasing the compression force does not cause a significant 
decrease in the rate of drug release.
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Generally, as presented in Table 7, the granulation process 
changes the exponent (n) values for both F1 and F2 formula-
tions at both hardness levels from Fickian to a non-Fickian 
release mechanism, which indicates the involvement of poly-
mer relaxation in the release process in addition to drug dif-
fusion. An exception is noted in F1 formulation prepared at 
hardness level (B) (Table 7). Moreover, release rate constant 
(K
p
) has been decreased by granulation process. This complies 
with previous discussion of effect of granulation process on 
drug release process, where granulation decreases porosity dur-
ing wet massing stage, and this reduction can delay dissolution 
media entrapment through the matrix at an early stage of dis-
solution test, which totally decreases the drug release rate.
In addition, Table 7 shows that the release mechanism 
of all tablets prepared originally from granules with and 
without sodium bicarbonate are predominantly controlled 
by diffusion and polymer relaxation where exponent (n) 
values are in a range of 0.5871–0.6822. Moreover, the addi-
tion of the gassing agent slightly increases the exponent (n) 
values, which indicates a little more contribution of polymer 
relaxation and erosion to release mechanism.46 This might be 
related to the movement of generated carbon dioxide bubbles 
from internal to peripheral sides of floating tablets, which 
increases the mass loss or polymer erosion behavior.
Furthermore, it has been noted that as sodium bicarbon-
ate concentration is increased from 0% up to 20% w/w, drug 
release rate (K
p
) is decreased in all tablets prepared originally 
from granules. This complies with the drug release profiles 
discussed earlier where increasing sodium bicarbonate con-
centration makes floating duration longer, which decreases 
the available surface area of tablets for DMU. In addition, 
a lower swelling rate is obtained, which means less dissolu-
tion medium entrapment in matrix tablet bodies, which is 
presented by a reduction in drug release rate. Furthermore, 
the effect of increasing sodium bicarbonate concentration on 
tablets prepared originally from powder mixture is not clear 
due to insufficient data points.
Conclusion
In this work, effervescent floating tablets of pentoxifylline 
were successfully prepared by using sodium bicarbonate 
as a gas-forming agent and a mixture of hydroxyethyl cel-
lulose and sodium alginate as polymeric matrix. The tablets 
could float on the surface of dissolution medium and sustain 
drug release over 24 hours. Tablets prepared with 20% w/w 
sodium bicarbonate at 50–54 N hardness showed satisfactory 
results with respect to floating lag time, total floating dura-
tion, swelling ability, and sustained drug release profile.
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